RESUMEN
BACKGROUND: Increasing functional residual capacity (FRC) or tidal volume (VT) reduces airway resistance and attenuates the response to bronchoconstrictor stimuli in animals and humans. What is unknown is which one of the above mechanisms is more effective in modulating airway caliber and whether their combination yields additive or synergistic effects. To address this question, we investigated the effects of increased FRC and increased VT in attenuating the bronchoconstriction induced by inhaled methacholine (MCh) in healthy humans. METHODS: Nineteen healthy volunteers were challenged with a single-dose of MCh and forced oscillation was used to measure inspiratory resistance at 5 and 19 Hz (R5 and R19), their difference (R5-19), and reactance at 5 Hz (X5) during spontaneous breathing and during imposed breathing patterns with increased FRC, or VT, or both. Importantly, in our experimental design we held the product of VT and breathing frequency (BF), i.e, minute ventilation (VE) fixed so as to better isolate the effects of changes in VT alone. RESULTS: Tripling VT from baseline FRC significantly attenuated the effects of MCh on R5, R19, R5-19 and X5. Doubling VT while halving BF had insignificant effects. Increasing FRC by either one or two VT significantly attenuated the effects of MCh on R5, R19, R5-19 and X5. Increasing both VT and FRC had additive effects on R5, R19, R5-19 and X5, but the effect of increasing FRC was more consistent than increasing VT thus suggesting larger bronchodilation. When compared at iso-volume, there were no differences among breathing patterns with the exception of when VT was three times larger than during spontaneous breathing. CONCLUSIONS: These data show that increasing FRC and VT can attenuate induced bronchoconstriction in healthy humans by additive effects that are mainly related to an increase of mean operational lung volume. We suggest that static stretching as with increasing FRC is more effective than tidal stretching at constant VE, possibly through a combination of effects on airway geometry and airway smooth muscle dynamics.
Asunto(s)
Broncoconstricción , Cloruro de Metacolina , Volumen de Ventilación Pulmonar , Humanos , Broncoconstricción/efectos de los fármacos , Broncoconstricción/fisiología , Volumen de Ventilación Pulmonar/fisiología , Volumen de Ventilación Pulmonar/efectos de los fármacos , Masculino , Femenino , Adulto , Adulto Joven , Cloruro de Metacolina/administración & dosificación , Broncoconstrictores/administración & dosificación , Pruebas de Provocación Bronquial/métodos , Capacidad Residual Funcional/fisiología , Capacidad Residual Funcional/efectos de los fármacos , Voluntarios Sanos , Resistencia de las Vías Respiratorias/efectos de los fármacos , Resistencia de las Vías Respiratorias/fisiología , Pulmón/efectos de los fármacos , Pulmón/fisiología , Volumen Espiratorio Forzado/fisiología , Volumen Espiratorio Forzado/efectos de los fármacosRESUMEN
Objectives: Nocturia with or without asthma is one of the aging diseases. Desmopressin has been used as a nasal spray for patients who are suffering from nocturia. This study determined the effects of desmopressin on isolated tracheal smooth muscle in vitro. Methods: We evaluated desmopressin's efficiency on isolated rat tracheal smooth muscle. Desmopressin was evaluated for the following effects on tracheal smooth muscle: (1) effect on resting tension; (2) effect on contraction brought on by parasympathetic mimetic 10-6 M methacholine; and (3) effect on electrically produced tracheal smooth muscle contractions. Results: As the concentration grew, desmopressin by itself had no impact on the trachea's baseline tension. Addition of desmopressin at doses of 10-5 M or above elicited a significant relaxation response to 10-6 M methacholine-induced contraction. Desmopressin could also inhibit spike contraction of the trachea induced by electrical field. Conclusion: According to this study, desmopressin at high quantities may prevent the trachea's parasympathetic activity. Due to its ability to block parasympathetic activity and lessen the contraction of the tracheal smooth muscle brought on by methacholine, Desmopressin nasal spray might help nocturia sufferers experience fewer asthma attacks.
Asunto(s)
Desamino Arginina Vasopresina , Contracción Muscular , Músculo Liso , Rociadores Nasales , Tráquea , Animales , Tráquea/efectos de los fármacos , Músculo Liso/efectos de los fármacos , Desamino Arginina Vasopresina/farmacología , Desamino Arginina Vasopresina/administración & dosificación , Ratas , Contracción Muscular/efectos de los fármacos , Masculino , Cloruro de Metacolina/administración & dosificación , Cloruro de Metacolina/farmacología , Humanos , Sistema Nervioso Parasimpático/efectos de los fármacosRESUMEN
BACKGROUND: Salbutamol is a cornerstone for relieving acute asthma symptoms, typically administered through a pressurized metered-dose inhaler (pMDI). Dry powder inhalers (DPIs) offer an alternative, but concerns exist whether DPIs provide an effective relief during an obstructive event. OBJECTIVE: We aimed to show non-inferiority of Salbutamol Easyhaler DPI compared to pMDI with spacer in treating methacholine-induced bronchoconstriction. Applicability of Budesonide-formoterol Easyhaler DPI as a reliever was also assessed. METHODS: This was a randomized, parallel-group trial in subjects sent to methacholine challenge (MC) test for asthma diagnostics. Participants with at least 20 % decrease in forced expiratory volume in 1 s (FEV1) were randomized to receive Salbutamol Easyhaler (2 × 200 µg), Ventoline Evohaler with spacer (4 × 100 µg) or Budesonide-formoterol Easyhaler (2 × 160/4.5 µg) as a reliever. The treatment was repeated if FEV1 did not recover to at least -10 % of baseline. RESULTS: 180 participants (69 % females, mean age 46 yrs [range 18-80], FEV1%pred 89.5 [62-142] %) completed the trial. Salbutamol Easyhaler was non-inferior to pMDI with spacer in acute relief of bronchoconstriction showing a -0.083 (95 % LCL -0.146) L FEV1 difference after the first dose and -0.032 (-0.071) L after the last dose. The differences in FEV1 between Budesonide-formoterol Easyhaler and Salbutamol pMDI with spacer were -0.163 (-0.225) L after the first and -0.092 (-0.131) L after the last dose. CONCLUSION: The study confirms non-inferiority of Salbutamol Easyhaler to Ventoline Evohaler with spacer in relieving acute bronchoconstriction, making Easyhaler a sustainable and safe reliever for MC test and supports its use during asthma attacks.
Asunto(s)
Albuterol , Asma , Broncoconstricción , Broncodilatadores , Inhaladores de Polvo Seco , Cloruro de Metacolina , Humanos , Cloruro de Metacolina/administración & dosificación , Femenino , Broncoconstricción/efectos de los fármacos , Masculino , Adulto , Asma/tratamiento farmacológico , Asma/fisiopatología , Persona de Mediana Edad , Albuterol/administración & dosificación , Volumen Espiratorio Forzado/efectos de los fármacos , Broncodilatadores/administración & dosificación , Broncodilatadores/uso terapéutico , Adulto Joven , Administración por Inhalación , Inhaladores de Dosis Medida , Adolescente , Pruebas de Provocación Bronquial/métodos , Resultado del Tratamiento , Anciano , Espaciadores de Inhalación , Combinación Budesonida y Fumarato de Formoterol/administración & dosificación , Combinación Budesonida y Fumarato de Formoterol/uso terapéuticoRESUMEN
BACKGROUND: Methods used to assess ventilation heterogeneity through inert gas washout have been standardised and showed high sensitivity in diagnosing many respiratory diseases. We hypothesised that nitrogen single or multiple breath washout tests, respectively nitrogen single breath washout (N2SBW) and nitrogen multiple breath washout (N2MBW), may be pathological in patients with clinical suspicion of asthma but normal spirometry. Our aim was to assess whether N2SBW and N2MBW are associated with methacholine challenge test (MCT) results in this population. We also postulated that an alteration in SIII at N2SBW could be detected before the 20% fall of forced expiratory volume in the first second (FEV1) in MCT. STUDY DESIGN AND METHODS: This prospective, observational, single-centre study included patients with suspicion of asthma with normal spirometry. Patients completed questionnaires on symptoms and health-related quality-of-life and underwent the following lung function tests: N2SBW (SIII), N2MBW (Lung clearance index (LCI), Scond, Sacin), MCT (FEV1 and sGeff) as well as N2SBW between each methacholine dose. RESULTS: 182 patients were screened and 106 were included in the study, with mean age of 41.8±14 years. The majority were never-smokers (58%) and women (61%). MCT was abnormal in 48% of participants, N2SBW was pathological in 10.6% at baseline and N2MBW abnormality ranged widely (LCI 81%, Scond 18%, Sacin 43%). The dose response rate of the MCT showed weak to moderate correlation with the subsequent N2SBW measurements during the provocation phases (ρ 0.34-0.50) but no correlation with N2MBW. CONCLUSIONS: Both MCT and N2 washout tests are frequently pathological in patients with suspicion of asthma with normal spirometry. The weak association and lack of concordance across the tests highlight that they reflect different but not interchangeable pathological pathways of the disease.
Asunto(s)
Asma , Pruebas Respiratorias , Pruebas de Provocación Bronquial , Cloruro de Metacolina , Nitrógeno , Espirometría , Humanos , Asma/diagnóstico , Asma/fisiopatología , Cloruro de Metacolina/administración & dosificación , Femenino , Masculino , Estudios Prospectivos , Adulto , Pruebas Respiratorias/métodos , Persona de Mediana Edad , Nitrógeno/análisis , Pruebas de Provocación Bronquial/métodos , Volumen Espiratorio Forzado , Pruebas de Función Respiratoria/métodos , Pulmón/fisiopatología , Broncoconstrictores/administración & dosificaciónRESUMEN
This document updates the recommendations of the bronchial challenge test with methacholine in children. It is based primarily on the recommendations contained in the guide on the technical standard of the bronchial challenge test for methacholine from the European Society of Respiratory Diseases. The main change is the recommendation to use PD20 (methacholine dose that causes a 20% drop in FEV1) instead of PC20 (methacholine concentration that causes a 20% drop in FEV1), which allows for comparable results when different devices and different protocols are used.
Este documento actualiza las recomendaciones de la prueba de provocación bronquial con metacolina en niños. Se basa fundamentalmente en las recomendaciones contenidas en la guía sobre el estándar técnico de la prueba de provocación bronquial de metacolina de la Sociedad Europea de Enfermedades Respiratorias. El principal cambio es la recomendación de utilizar la PD20 (dosis de metacolina que provoca una caída de 20% del VEF1) en vez de PC20 (concentración de metacolina que provoca una caída del 20% en el VEF1), lo cual permite tener resultados comparables cuando se usan diferentes dispositivos y diferentes protocolos.
Asunto(s)
Humanos , Niño , Pruebas de Provocación Bronquial/métodos , Cloruro de Metacolina/administración & dosificación , Hiperreactividad Bronquial/diagnóstico , Hiperreactividad Bronquial/fisiopatologíaRESUMEN
Existe poca información en niños acerca de cual valor de VEF1, si el más alto o el más bajo, debe ser considerado para el cálculo de la PC20 de metacolina. Veinte niños asmáticos atópicos, previamente entrenados hasta alcanzar maniobras de capacidad vital forzada reproducibles, fueron estudiados para determinar si había diferencias en las PC20 de metacolina calculadas con los mayores o los menores valores de VEF1. Las diferencias entre las PC20 usando uno u otro valor de VEF1 no fueron estadísticamente significativas (ANOVA). Hubo una correlación significativa entre las PC20 calculadas con ambos métodos (r= 0,93, p< 0,05). El presente estudio demuestra que, en niños asmáticos entrenados hasta lograr maniobras de capacidad vital forzada reproducible, la PC20 puede ser determinada usando el valor más alto o más bajo de VEF1